Grifols makes net profit of €133.5 million in the first half of 2012
The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of 2012 was €133.5 million, seven times that of the previous year. The company’s success is attributed to its wide geographical consumer base and the recent purchase of US based Talecris Plasma Resources.
Barcelona (ACN).- The Catalan pharmaceutical company Grifols, specialised in the production of plasma derivates, has seen its turnover increase by 15% in the first half of 2012, to €1.316,7 billon euros. Ranked third for world production of pharmaceuticals derived from blood plasma, the company reported in June a total net profit of €133.5 million for the first half of the year, increasing its return by almost sevenfold compared to last year. The company has upgraded its operational efficiency after the integration of US based Talecris and estimates that this will generate $300 million per year beyond 2015. Over 90% of Grifols’ profit comes from the international market. Joint sales in Spain, Italy, Portugal and Greece account for 13% of total revenues.
As a global company, Grifols markets and distributes its products in more than 90 countries and its various subsidiaries operate directly in 24 countries. The geographical breadth of the pharmaceutical producer minimises its foreign exchange risk. However the recent fluctuations in the dollar have been favourable for the company and sales in the United States have increased by about 20%.
After the purchase of Talecris, over 90% of Grífols’ revenue comes from outside of Spain, accounting for 1.2 billion euros of sales in the first quarter. The reported revenue increased by 107.2%, although they do not include sales by Talecris from January to May 2011 as the company was being purchased during this period.